382 related articles for article (PubMed ID: 27060634)
1. Immunocytokines for cancer treatment: past, present and future.
Neri D; Sondel PM
Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
[TBL] [Abstract][Full Text] [Related]
2. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
Hutmacher C; Neri D
Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
Neri D
Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
5. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
Murer P; Neri D
N Biotechnol; 2019 Sep; 52():42-53. PubMed ID: 30991144
[TBL] [Abstract][Full Text] [Related]
6. The present and future of immunocytokines for cancer treatment.
Gout DY; Groen LS; van Egmond M
Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
[TBL] [Abstract][Full Text] [Related]
7. Antibody fusions with immunomodulatory proteins for cancer therapy.
Müller D
Pharmacol Ther; 2015 Oct; 154():57-66. PubMed ID: 26145167
[TBL] [Abstract][Full Text] [Related]
8. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
9. [Cancer immunotherapy].
Vakkila J; Pihkala U
Duodecim; 1999; 115(7):785-94. PubMed ID: 11859512
[No Abstract] [Full Text] [Related]
10. Immunocytokines: a novel class of potent armed antibodies.
Pasche N; Neri D
Drug Discov Today; 2012 Jun; 17(11-12):583-90. PubMed ID: 22289353
[TBL] [Abstract][Full Text] [Related]
11. An overview of cancer immunotherapeutic strategies.
Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
[TBL] [Abstract][Full Text] [Related]
12. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
Alderson KL; Sondel PM
J Biomed Biotechnol; 2011; 2011():379123. PubMed ID: 21660134
[TBL] [Abstract][Full Text] [Related]
13. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
14. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
[TBL] [Abstract][Full Text] [Related]
15. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
Young PA; Morrison SL; Timmerman JM
Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic antibodies and antibody fusion proteins.
Rohrbach P; Broders O; Toleikis L; Dübel S
Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
[No Abstract] [Full Text] [Related]
17. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
18. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
Müller D
BioDrugs; 2014 Apr; 28(2):123-31. PubMed ID: 24018469
[TBL] [Abstract][Full Text] [Related]
19. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.
Huang MA; Krishnadas DK; Lucas KG
J Immunol Res; 2015; 2015():675269. PubMed ID: 26587548
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
